相关实验视频

Updated: Jun 28, 2025

Cigarette Smoke Exposure in Mice using a Whole-Body Inhalation System

Cigarette Smoke Exposure in Mice using a Whole-Body Inhalation System

Published on: October 22, 2020

古古尔斯特可以保护人免受烟雾引起的COPD相关的肺炎

Manpreet Kaur¹, Jai Malik², Amarjit S Naura³

¹Department of Biochemistry, Panjab University, Chandigarh, 160014, India.

Cell biochemistry and biophysics

|April 12, 2024

概括

古古斯特是一种来自Commiphora wightii的化合物,在老鼠模型中有效减少肺炎并改善肺功能,这种老鼠模型的慢性阻塞性肺病 (COPD) 是由香烟烟雾 (CS) 引起的. 这表明guggulsterone可能对CS诱导的COPD提供保护作用.

科学领域:

肺病学和呼吸系统医学
药理学和治疗学药理学和治疗学
炎症和免疫学炎症和免疫学

背景情况:

慢性阻塞性肺病 (COPD) 是一个主要的健康问题,烟雾暴露是主要的风险因素.
古古尔斯特是Commiphora wightii的组成部分,以前已经显示出对弹性酶诱导的COPD的保护作用.
在CS诱导的COPD模型中,guggulsterone的疗效在很大程度上仍未得到研究.

研究的目的:

评估guggulsterone在改善与CS诱导的COPD相关的肺炎中的治疗潜力.
为了研究guggulsterone对炎症细胞透,细胞因子生产和肺功能在CS暴露的小鼠模型的影响.

主要方法:

雄性BALB/c小鼠每天连续四天暴露在香烟烟雾中.
在CS暴露前一个小时,Guggulsterone被口服每天10mg/kg,一个小时.
测量了肺功能,并分析了支气管洗液 (BALF) 和肺组织的炎症标志物和基因表达 (RT-PCR).

主要成果:

在BALF和肺组织中,CS暴露显著增加了炎症细胞 (中性粒细胞,巨细胞) 和促炎细胞因子 (TNF-α,IL-1β,IL-6,G-CSF,KC,MCP-1).
古古尔斯特的使用显著减少了CS诱导的炎症细胞透,并抑制了关键的促炎媒介体的表达和产生.
古古斯特治疗改善了肺功能参数,并调节了肺中的矩阵金属蛋白酶-9 (MMP-9) 和其抑制剂 (TIMP-1) 的表达.

结论:

在小鼠模型中,古古斯特对烟雾诱导的COPD相关的肺炎具有显著的保护作用.
该化合物通过调节炎性细胞招募和促炎性细胞因子和矩阵降解酶的表达而起作用.
古古斯特作为治疗或预防慢性阻塞性肺病的潜在治疗剂具有前景.

关键词:

慢性慢性肺炎是一种慢性慢性肺炎,COPD是一种慢性肺炎.香烟烟雾的烟雾是什么意思在Guggulsterone中使用.炎症炎症是一种炎症.氧化应激是一种氧化应激.

更多相关视频

Isolation of Mouse Respiratory Epithelial Cells and Exposure to Experimental Cigarette Smoke at Air Liquid Interface

Isolation of Mouse Respiratory Epithelial Cells and Exposure to Experimental Cigarette Smoke at Air Liquid Interface

Published on: February 21, 2011

Author Spotlight: Development and Characterization of an In Vitro Model to Study Chronic Cigarette Smoke Exposure and Its Impact on Airway Epithelial Cells in COPD Research

Author Spotlight: Development and Characterization of an In Vitro Model to Study Chronic Cigarette Smoke Exposure and Its Impact on Airway Epithelial Cells in COPD Research

Published on: July 12, 2024

相关概念视频

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation

Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...

COPD: Pathogenesis and Clinical Features

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.

COPD: Management Using Bronchodilators and Corticosteroids

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...

Chronic Obstructive Pulmonary Disease-V: Management

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation